Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: a pooled analysis of 557 trials, Cancer, vol.121, pp.3335-3377, 2015. ,
Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective, J Natl Cancer Inst Monogr, pp.7-9, 1996. ,
Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov, Contemp Clin Trials, vol.43, pp.1-9, 2007. ,
Statistical challenges in the analysis of health-related quality of life in Cancer clinical trials, J Clin Oncol, vol.34, pp.1953-1959, 2016. ,
Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, vol.16, pp.139-183, 1998. ,
Measurement of health status. Ascertaining the minimal clinically important difference, Control Clin Trials, vol.10, pp.407-422, 1989. ,
Defining clinically meaningful change in health-related quality of life, J Clin Epidemiol, vol.56, pp.395-407, 2003. ,
Interpretation of quality of life changes, Qual Life Res, vol.2, pp.221-227, 1993. ,
Effect sizes for interpreting changes in health status, Med Care, vol.27, pp.178-89, 1989. ,
Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life, J Clin Epidemiol, vol.52, pp.861-73, 1999. ,
Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening, Qual Life Res, vol.11, pp.207-228, 2002. ,
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes, J Clin Epidemiol, vol.61, pp.102-111, 2008. ,
Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) anemia and fatigue scales, J Pain Symptom Manag, vol.24, pp.547-61, 2002. ,
Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials, Expert Rev Pharmacoecon Outcomes Res, vol.11, pp.549-59, 2011. ,
Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma, Health Qual Life Outcomes, vol.8, p.79, 2010. ,
Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30, Eur J Cancer, vol.48, pp.1713-1734, 2012. ,
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients, Ann Oncol, vol.22, pp.2107-2119, 2011. ,
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, vol.6, p.1000097, 2009. ,
Evaluating minimal important differences for the FACT-melanoma quality of life questionnaire, Value Health, vol.12, pp.1144-50, 2009. ,
Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer, J Pain Symptom Manag, vol.46, pp.192-200, 2013. ,
Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer, Asia Pac J Clin Oncol, vol.10, pp.109-126, 2014. ,
Minimal important differences in the EORTC QLQ-C15-PAL to determine meaningful change in palliative advanced cancer patients, Asia Pac J Clin Oncol, vol.12, pp.38-46, 2016. ,
Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma, Health Qual Life Outcomes, vol.15, p.247, 2017. ,
Minimal clinically important differences in quality of life scores of oral cavity and oropharynx cancer patients, Ann Surg Oncol, vol.21, pp.2773-81, 2014. ,
What is a clinically meaningful change on the functional assessment of Cancer therapy-lung (FACT-L) questionnaire? Results from eastern cooperative oncology group (ECOG) study 5592, J Clin Epidemiol, vol.55, pp.285-95, 2002. ,
Estimating clinically meaningful changes for the functional assessment of Cancer therapy--prostate: results from a clinical trial of patients with metastatic hormonerefractory prostate cancer, Value Health, vol.12, pp.124-133, 2009. ,
Minimal clinically important difference of the multidimensional fatigue symptom inventory-short form (MFSI-SF) for fatigue worsening in Asian breast Cancer patients, J Pain Symptom Manag, vol.55, pp.992-999, 2018. ,
Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACTcog) in breast cancer patients, J Clin Epidemiol, vol.67, pp.811-831, 2014. ,
The minimal clinical important difference in the World Health Organization quality of life instrument--100, Support Care Cancer, vol.21, pp.1295-301, 2013. ,
A brief symptom index for advanced renal cell carcinoma, Health Qual Life Outcomes, vol.4, p.68, 2006. ,
A combination of distribution-and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale, J Clin Epidemiol, vol.57, pp.898-910, 2004. ,
Validation of the functional assessment of cancer therapy--lung symptom index-12 (FLSI-12), Lung Cancer, vol.57, pp.339-386, 2007. ,
Minimal important difference of the 6-minute walk distance in lung cancer, Chron Respir Dis, vol.12, pp.146-54, 2015. ,
The self-reported physical activity scale for the elderly (PASE) is a valid and clinically applicable measure in lung cancer, Support Care Cancer, vol.23, pp.3211-3219, 2015. ,
Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy, BMC Cancer, vol.13, p.165, 2013. ,
Minimal clinically important difference in the physical, emotional, and Total symptom distress scores of the Edmonton symptom assessment system, J Pain Symptom Manag, vol.51, pp.262-271, 2016. ,
Comparison of distribution-and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors, Health Serv Res, vol.47, pp.1902-1927, 2012. ,
A new approach to combining clinical relevance and statistical significance for evaluation of quality of life changes in the individual patient, J Clin Epidemiol, vol.63, pp.171-180, 2010. ,
Three methods for minimally important difference: no relationship was found with the net proportion of patients improving, J Clin Epidemiol, vol.60, pp.448-55, 2007. ,
Comparing and validating simple measures of patient-reported peripheral neuropathy for oncology clinical trials: NCCTG N0897 (Alliance) a pooled analysis of 2440 patients, SOJ Anesthesiol Pain Manag, vol.2, 2015. ,
Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials, Support Care Cancer, vol.19, pp.1753-60, 2011. ,
Estimating minimally important differences for the worst pain rating of the brief pain inventory-short form, J Support Oncol, vol.9, pp.72-80, 2011. ,
Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study, Cancer Manag Res, vol.8, pp.1-10, 2016. ,
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, vol.5, p.70, 2007. ,
Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population, Support Care Cancer, vol.18, pp.307-322, 2010. ,
Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy, Qual Life Res, vol.25, pp.2535-2576, 2016. ,
Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases, Qual Life Res, vol.27, pp.1089-98, 2018. ,
Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference?, Qual Life Res, vol.23, pp.1427-1461, 2014. ,
Assessing responsiveness of cancer-related fatigue instruments: distribution-based and individual anchor-based methods, Oncologist, vol.12, pp.495-504, 2007. ,
Minimally important difference for the expanded prostate Cancer index composite short form, Urology, vol.85, pp.101-106, 2015. ,
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma, Ann Oncol, vol.17, pp.304-316, 2006. ,
Measurement properties of the work limitations questionnaire were sufficient among cancer survivors, Qual Life Res, vol.23, pp.515-540, 2014. ,
EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund survey of sicker adults in Canada, Qual Life Res, vol.25, pp.3009-3025, 2016. ,
Interpretation of the Swedish self evaluation of communication experiences after laryngeal cancer: cutoff levels and minimum clinically important differences, Head Neck, vol.38, pp.689-95, 2016. ,
Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases, Support Care Cancer, vol.23, pp.2731-2738, 2015. ,
Minimal clinically important differences in the brief pain inventory in patients with bone metastases, Support Care Cancer, vol.21, pp.1893-1902, 2013. ,
Measurement and interpretation of social distress using the social difficulties inventory (SDI) ,
, Eur J Cancer, vol.44, pp.1529-1564, 2008.
Minimally important differences were estimated for the functional assessment of Cancer therapy-colorectal (FACT-C) instrument using a combination of distribution-and anchor-based approaches, J Clin Epidemiol, vol.58, pp.1241-51, 2005. ,
Minimally important differences were estimated for six patient-reported outcomes measurement information system-Cancer scales in advanced-stage cancer patients, J Clin Epidemiol, vol.64, pp.507-523, 2011. ,
Using multiple anchor-and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of Cancer therapy-biologic response modifiers (FACT-BRM) instrument, Value Health, vol.8, pp.117-144, 2005. ,
An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases, Support Care Cancer, vol.20, pp.3307-3320, 2012. ,
Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time, Health Qual Life Outcomes, vol.14, p.167, 2016. ,
Interpretation of changes in healthrelated quality of life: the remarkable universality of half a standard deviation, Med Care, vol.41, pp.582-92, 2003. ,
Methodology of healthrelated quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review, Soc Sci Med, vol.48, p.122, 1999. ,
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma, Eur J Cancer, vol.46, pp.2753-62, 2010. ,